Mallawaarachchi Kanchana Viraj, Gangani Chathurika, Bouazzi Dorra, Medianfar Cecilia E, Christensen Robin, Jemec Gregor B E
Department of Dermatology, Base Hospital - Balangoda, Balangoda, Sri Lanka.
Department of Pediatrics, Base Hospital - Balangoda, Balangoda, Sri Lanka.
Dermatology. 2025 Jul 7:1-5. doi: 10.1159/000539336.
Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent, debilitating skin disease of the hair follicles in the apocrine gland-bearing areas of the body. The global HS prevalence has been reported in the range of 0.00033-4.1%. It is reportedly rarer in Asia.
The study aimed to establish the prevalence of hidradenitis suppurativa (HS) in a Sri Lankan hospital setting. An explorative, cross-sectional, descriptive study was done on a sample of accompanying healthy persons to patients at Base Hospital, Balangoda, Sri Lanka. The study was conducted over a 6-month period (November 1st, 2022, to April 30th, 2023) and was a part of the Global Hidradenitis Suppurativa Atlas (GHiSA) initiative. The data were collected using validated self-administered questionnaire. When the questionnaire indicated HS (screen-positive), the study participant was referred to the consultant dermatologist, who examined the individual and confirmed the final diagnosis based on three obligatory diagnostic criteria (i.e., typical lesion, typical topography, and the chronicity and recurrence).
Of 993 participants, the prevalence of HS was 0.2 (95% confidence interval 0.06%-0.73%). The difference in median age between two groups (i.e., individuals with HS - positive group and the control group) was statistically significant (p = 0.01802). The HS group was relatively younger with a median age of 26.5 (23.8-29.3) years, while that of the control group was 54.0 (48.0-59.0).
Hidradenitis suppurativa is rare in Sri Lanka as in other Asia-pacific countries.
化脓性汗腺炎（HS）是一种慢性、炎症性、复发性、使人衰弱的皮肤病，发生于身体有顶泌汗腺的毛囊部位。据报道，全球HS患病率在0.00033%-4.1%之间。据报道，在亚洲这种病较为罕见。
本研究旨在确定化脓性汗腺炎（HS）在斯里兰卡一家医院环境中的患病率。对斯里兰卡巴朗戈达基地医院患者的陪同健康人员样本进行了一项探索性、横断面、描述性研究。该研究在6个月期间（2022年11月1日至2023年4月30日）进行，是全球化脓性汗腺炎地图集（GHiSA）倡议的一部分。数据通过经过验证的自填问卷收集。当问卷显示HS（筛查阳性）时，研究参与者被转介给皮肤科顾问医生，医生对其进行检查，并根据三个必要诊断标准（即典型病变、典型部位以及慢性和复发性）确认最终诊断。
在993名参与者中，HS患病率为0.2（95%置信区间0.06%-0.73%）。两组（即HS阳性组个体和对照组）的中位年龄差异具有统计学意义（p = 0.01802）。HS组相对年轻，中位年龄为26.5（23.8-29.3）岁，而对照组为54.0（48.0-59.0）岁。
与其他亚太国家一样，化脓性汗腺炎在斯里兰卡较为罕见。
